EUVIMEDEUVIMED entdecken
Crossref

Broad antifibrotic activities of AK3280 in pulmonary, hepatic, cardiac, and skin fibrosis animal models

Zhao Gao, Sushan Cao, Haiqing Yuan, Jim Zhen Wu, Gang Zou

International Immunopharmacology · 2025

DOI: 10.1016/j.intimp.2025.114337 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2025. Verfasst von Zhao Gao und 4 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Ark Biopharmaceutical Co., Ltd, Shanghai 201203, China. Hauptthemen laut MEDLINE: Skin, Antifibrotic Agents, Pulmonary Fibrosis, Skin Diseases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 64 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Fibrosis is the pathological outcome of many chronic inflammatory diseases, affecting various human organs. It is a significant contributor to global morbidity and mortality that affects nearly half of the elderly population. Pirfenidone (PFD) and nintedanib are approved by the FDA for treating pulmonary fibrosis, but these treatments are associated with poor tolerability and limited efficacy. Moreover, no antifibrotic drugs are approved for other fibrosis-related diseases, highlighting an urgent unmet medical need for more effective therapies. Here we report the in vivo pharmacological activities of AK3280, a novel, orally bioavailable small molecule designed to enhance pharmacokinetics, antifibrotic activity, and tolerability over PFD. AK3280 demonstrated antifibrotic effects across multiple organs, including the lungs, liver, heart, and skin, in various animal models. These results suggest that AK3280 holds promise as a clinically beneficial antifibrotic therapy for a range of fibrotic diseases, especially pulmonary, hepatic, cardiac, and skin fibrosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SkinAntifibrotic AgentsPulmonary FibrosisSkin DiseasesAnimalsDisease Models, AnimalFibrosisHumansLungMiceLiverMalePyridonesMyocardiumLiver CirrhosisRats

Stichwörter der Autor:innen

AK3280Animal modelAntifibroticFibrosisPirfenidone

Substanzen

Antifibrotic AgentsPyridonespirfenidone

Autor:innen und Institutionen

  • Shanghai Ark Biopharmaceutical Co., Ltd, Shanghai 201203, China.
  • Shanghai Ark Biopharmaceutical Co., Ltd, Shanghai 201203, China. Electronic address: gang.zou@arkbiosciences.com.

Zitieren

APA

Gao, Z., Cao, S., Yuan, H., Wu, J. Z., & Zou, G. (2025). Broad antifibrotic activities of AK3280 in pulmonary, hepatic, cardiac, and skin fibrosis animal models. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2025.114337

Vancouver

Gao Z, Cao S, Yuan H, Wu JZ, Zou G. Broad antifibrotic activities of AK3280 in pulmonary, hepatic, cardiac, and skin fibrosis animal models. International Immunopharmacology. 2025. doi:10.1016/j.intimp.2025.114337

BibTeX
@article{Gao2025,
  author = {Gao, Zhao and Cao, Sushan and Yuan, Haiqing and Wu, Jim Zhen and Zou, Gang},
  title = {Broad antifibrotic activities of AK3280 in pulmonary, hepatic, cardiac, and skin fibrosis animal models},
  journal = {International Immunopharmacology},
  year = {2025},
  doi = {10.1016/j.intimp.2025.114337}
}
Kostenlos starten →